# **I** Alnylam Corporate Fact Sheet

#### Harnessing a Revolution in Biology for Human Health®

Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutics, with three approved products in the market.

We are dedicated to demonstrating that bold science, perseverance, and passion can come together to improve patients' lives. Because we believe that no patient should have to wait for hope, we accept the challenges inherent in scientific discovery and the creation of a new class of medicines.

### **Rooted in Nobel Prize-Winning Science**

Heralded as one of the most promising and rapidly advancing frontiers in biology and drug discovery, RNAi therapeutics are treating disease in a entirely new way. The discovery of RNAi was awarded the 2006 Nobel Prize for Physiology or Medicine.

We are committed to harnessing this revolution in biology and to delivering new products to patients on a sustainable basis. Alnylam scientists and collaborators have published research on RNAi therapeutics in over 250 peer-reviewed papers, including many in the world's top scientific journals such as *Nature, Nature Medicine, Nature Biotechnology, Cell, The New England Journal of Medicine* and *The Lancet.* 

#### **Realizing the Promise of RNAi**

Developing and realizing the promise of RNAi is our heritage and our future. RNAi has led to a breakthrough in understanding how genes function in cells. Through Alnylam's efforts, RNAi has emerged as a powerful approach with the potential to transform treatment for patients with limited options.

Our RNAi therapeutics platform is the core of Alnylam's discovery and development strategy. This platform has the potential to enable a streamlined path to market for our product candidates and fuels sustainable pipeline growth as we continue to evolve into a fully integrated biopharmaceutical company.

We believe the investigational medicines based on our RNAi therapeutics platform have the potential to advance the care of patients, with features including infrequent, low-volume, subcutaneous dosing; a potent and durable drug effect; potential for improved efficacy with sustained drug activity; and room temperature stability.

#### **Products**

Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), Leqvio®\* (inclisiran), and AMVUTTRA® (vutrisiran).

Visit ONPATTRO.com, GIVLAARI.com, OXLUMO.com, and AMVUTTRA.com for more information, including full Prescribing Information.

#### **Patient Access Philosophy**

Alnylam is committed to advancing innovative RNAi therapeutics for the treatment of patients with life-threating diseases. For patients and society to benefit, these innovations must reach the people who need them. The overarching objective of Alnylam's Patient Access Philosophy is to make the therapies we develop available to those who may benefit from them. Alnylam's Patient Access Philosophy commits Alnylam to act with urgency for patients, proactively pursue value-based agreements with payers, and to not increase the annualized price of its medicines above the consumer price index (CPI-U) unless there has been valuable new innovation achieved.

#### Alnylam Assist®

As part of Alnylam's commitment to making therapies available to those who may benefit from them, Alnylam Assist offers a wide range of services to guide patients through treatment with ONPATTRO, GIVLAARI, OXLUMO and AMVUTTRA, including financial assistance options for eligible patients, and benefit verification and claims support. Patients will have access to dedicated Case Managers who can provide personalized support throughout the treatment process and Patient Education Liaisons who are available to help patients gain a better understanding of the disease. Visit AlnylamAssist.com for more information.

#### **Product Pipeline**

From science to medicine, bench to bedside, possibility to patient, Alnylam has advanced RNAi therapeutics from raw, groundbreaking, Nobel Prize-winning science to a powerful product engine.

\*Licensed to Novartis Continued on back page



Our deep pipeline of investigational RNAi therapeutics is focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Disease, Infectious Disease, and CNS/Ocular Diseases. Four of our product candidates are in late-stage development: lumasiran for severe primary hyperoxaluria type 1, patisiran label expansion for ATTR amyloidosis, vutrisiran for ATTR amyloidosis, hypercholesterolemia, and fitusiran for hemophilia and other rare bleeding disorders.

Genetic Medicines Cardio		o-Metabolic Diseases		nfectious Diseases	CNS/Ocular Diseases		
		HUMAN POC <sup>1</sup>	BREAKTHROUGH DESIGNATION	EARLY/MID STAGE (IND or CTA Filed-Phase 2)	LATE STAGE (Phase 2-Phase 3)	REGISTRATION/ COMMERCIAL <sup>2</sup> (OLE/Phase 4/IIS/registries)	COMMERCIAL RIGHTS
ONPATTRO® (patisiran)³	hATTR Amyloidosis-PN	2/	<mark>2</mark>			•	Global
GIVLAARI® (givosiran)4	Acute Hepatic Porphyria	2/	2			•	Global
OXLUMO* (lumasiran) <sup>5</sup>	Primary Hyperoxaluria Type 1	2/	R			•	Global
Leqvio® (inclisiran) <sup>6</sup>	Hypercholesterolemia	2/				•	Milestones & up to 20% Royalties <sup>7</sup>
AMVUTTRA® (vutrisiran)8	hATTR Amyloidosis-PN	2/				•	Global
Patisiran	ATTR Amyloidosis-CM Label Expansion	2/				•	Global
Vutrisiran	ATTR Amyloidosis-CM	2/			•		Global
ALN-TTRsc04	ATTR Amyloidosis	2/		•			Global
Fitusiran	Hemophilia	2/			•		15-30% Royalties
Cemdisiran (+/- Pozelimab) <sup>9</sup>	Complement-Mediated Diseases	2/			•		Global Milestone/Royalty
Belcesiran <sup>10</sup>	Alpha-1 Liver Disease	2/		•			Ex-U.S. option post-Phase 3
ALN-HBV02 <sup>11</sup> (VIR-2218)	Hepatitis B Virus Infection	2/		•			50-50 option post-Phase 2
Zilebesiran (ALN-AGT)	Hypertension	2/		•			Global
ALN-HSD	NASH	2/		•			Royalty
ALN-APP	Alzheimer's Disease; Cerebral Amyloid Angiopathy			•			50-50
ALN-PNP	NASH			•			50-50
ALN-KHK	Type 2 Diabetes			•			Global

POC, proof of concept – defined as having demonstrated target gene knockdown and/or additional evidence of activity in clinical studies

As of December 2022

# **Expanding Global Presence**

Headquartered in Cambridge, Mass., Alnylam employs over 2,000 people worldwide and is rapidly growing globally, with additional offices in the United States and 20 other countries.

## Alnylam P⁵x25

Commencing in 2022, Alnylam is executing on its "Alnylam P<sup>5</sup>x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile by 2025.

We are relentless in our pursuit of the development of new therapies because patients deserve discovery. Every single one of them.

For more information about our people, products, science and pipeline of investigational RNAi therapeutics, please visit alnylam.com and engage with us on Twitter at @Alnylam and on LinkedIn.



<sup>&</sup>lt;sup>2</sup> Includes marketing application submissions

<sup>&</sup>lt;sup>3</sup> Approved in the U.S. and Canada for the polyneuropathy (PN) of hATTR amyloidosis in adults, and in the EU, Japan and other countries for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 PN

Approved in the U.S., Brazil and Canada for the treatment of adults with acute hepatic porphyria (AHP), and in the EU and Japan for the treatment of AHP in adults and adolescents aged 12 years and older Approved in the U.S. for the treatment of primary hyperoxaluria type 1 to lower urinary and plasma oxalate levels in children and adults, and in the EU and Brazil for the treatment of primary hyperoxaluria type 1 in all age groups

<sup>&</sup>lt;sup>6</sup> Novartis has obtained global rights to develop, manufacture and commercialize inclisiran

<sup>&</sup>lt;sup>7</sup>50% of inclisiran royalty revenue from Novartis will be payable to Blackstone by Alnylam <sup>8</sup> Approved in the U.S. for the polyneuropathy (PN) of hATTR amyloidosis in adults, and in the EU and Japan for the treatment of hATTR amyloidosis with stage 1 or 2 polyneuropathy

<sup>9</sup>Alnylam and Regeneron are evaluating potential combinations of the investigational therapeutics cemdisiran and pozelimab

<sup>&</sup>lt;sup>10</sup> Dicerna is leading and funding development of Belcesiran

<sup>&</sup>lt;sup>11</sup> Vir is leading and funding development of ALN-HBV02